Henshaw Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Henshaw Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,227	Closed	-$531K	–	164
2025 Q3	$531K	Sell	13,227 -814	-6%	-$30.6K	0.02%	175
2025 Q2	$467K	Hold	14,041	–	–	0.02%	242
2025 Q1	$411K	Hold	14,041	–	–	0.02%	249
2024 Q4	$461K	Hold	14,041	–	–	0.02%	234
2024 Q3	$624K	Hold	14,041	–	–	0.03%	190
2024 Q2	$605K	Buy	14,041 +159	+1%	+$5.74K	0.03%	156
2024 Q1	$406K	Hold	13,882	–	–	0.02%	205
2023 Q4	$309K	Hold	13,882	–	–	0.02%	237
2023 Q3	$344K	Buy	+13,882	New	+$367K	0.02%	208
2021 Q4	–	Sell	-4,727	Closed	-$218K	–	325
2021 Q3	$218K	Hold	4,727	–	–	0.01%	308
2021 Q2	$261K	Hold	4,727	–	–	0.02%	305
2021 Q1	$244K	Hold	4,727	–	–	0.02%	309
2020 Q4	$205K	Buy	+4,727	New	+$187K	0.02%	330
2020 Q3	–	Sell	-5,022	Closed	-$269K	–	315
2020 Q2	$269K	Buy	+5,022	New	+$233K	0.02%	236

Other funds holding AGIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Henshaw Capital's AGIO Position: Q4 2025 in Review

Henshaw Capital sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 13,227 shares — an estimated $531K sold.

Henshaw Capital first reported a position in AGIO in Q2 2020 and held it in 14 quarters. The position peaked at $624K in Q3 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

Henshaw Capital reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Henshaw Capital sold 13,227 Agios Pharmaceuticals shares in Q4 2025, an estimated $531K.
Henshaw Capital first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Henshaw Capital's Agios Pharmaceuticals position peaked at $624K in Q3 2024.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.